Your browser doesn't support javascript.
loading
Clinical predictors of symptom improvement failure in gastroparesis.
Amjad, Waseem; Doycheva, Iliana; Kamal, Faisal; Malik, Adnan; Pandu, Asha; Shabbir, Muhammad Asim; Mumtaz, Mirrah; Batool, Asra; Ukleja, Andrew.
Affiliation
  • Amjad W; Internal Medicine, Albany Medical Center, Albany NY (Waseem Amjad, Asha Pandu, Muhammad Shabbir).
  • Doycheva I; Clinical Research, Harvard Medical School, Boston MA (Waseem Amjad).
  • Kamal F; Endocrinology and Metabolism, University of Chicago, Chicago IL (Iliana Doycheva).
  • Malik A; Gastroenterology and Hepatology, University of Tennessee, Memphis, TN (Faisal Kamal).
  • Pandu A; Internal Medicine, Loyola University Medical Center, Chicago, IL (Adnan Malik).
  • Shabbir MA; Internal Medicine, Albany Medical Center, Albany NY (Waseem Amjad, Asha Pandu, Muhammad Shabbir).
  • Mumtaz M; Internal Medicine, Albany Medical Center, Albany NY (Waseem Amjad, Asha Pandu, Muhammad Shabbir).
  • Batool A; Endocrinology, Albany Medical Center, Albany, NY (Mirrah Mumtaz).
  • Ukleja A; Gastroenterology and Hepatology, Albany Medical Center, Albany, NY (Asra Batool).
Ann Gastroenterol ; 35(2): 119-126, 2022.
Article in En | MEDLINE | ID: mdl-35479589
ABSTRACT

Background:

The aim of this study was to determine clinical predictors of gastroparesis outcomes.

Methods:

Between September 30, 2009 and January 31, 2020, we identified patients with gastroparesis diagnosed based on a 99mTc sulfur-labeled gastric emptying test. The patients who had no symptom improvement at 4 and 12 weeks were considered to have failed to show clinical improvement. Logistic regression was used to compute the association between different factors and clinical outcomes.

Results:

We identified 320 patients (mean age 47.5±5.3 years, 70.3% female, 71.3% Whites). Failure of clinical improvement was seen in 34.7% patients at 4 weeks and 27.5% at 12 weeks after the gastroparesis diagnosis. At 4 weeks, chronic kidney disease (adjusted odds ratio [aOR] 2.62, 95% confidence interval [CI] 1.31-5.26; P=0.007) and body mass index (BMI) <18.5 kg/m2 (aOR 9.90, 95%CI 2.98-32.93; P<0.001) were associated with a lack of improvement, whereas type 2 diabetes mellitus (T2DM) was associated with better clinical outcomes (aOR 0.50, 95%CI 0.25-0.99; P=0.047). At 12 weeks, subjects who had undergone post-bariatric surgery had no improvement of their gastroparesis symptoms (aOR 2.43, 95%CI 1.01-5.82; P=0.047), whereas T2DM was associated with clinical improvement (aOR 0.46, 95%CI 0.22-0.95; P=0.035). The subgroup analysis showed that BMI <18.5 kg/m2 in non-diabetics and peripheral neuropathy in diabetics were associated with persistent symptoms.

Conclusions:

Gastroparesis patients with T2DM had significant symptom improvement. A history of bariatric surgery and renal failure were associated with worse clinical improvement. Peripheral neuropathy in diabetics was associated with persistent symptoms.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Ann Gastroenterol Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Ann Gastroenterol Year: 2022 Document type: Article